{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361694366709449984.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.eururo.2020.01.012"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0302283820300488?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0302283820300488?httpAccept=text/plain"}},{"identifier":{"@type":"PMID","@value":"32222292"}},{"identifier":{"@type":"HANDLE","@value":"20.500.12530/82468"}},{"identifier":{"@type":"HANDLE","@value":"https://repository.ubn.ru.nl/handle/2066/217644"}},{"identifier":{"@type":"HANDLE","@value":"20.500.11768/108604"}},{"identifier":{"@type":"HANDLE","@value":"11443/2886"}},{"identifier":{"@type":"HANDLE","@value":"2066/217644"}},{"identifier":{"@type":"HANDLE","@value":"2078.1/226802"}},{"identifier":{"@type":"HANDLE","@value":"11585/801865"}},{"identifier":{"@type":"HANDLE","@value":"1854/LU-8674279"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019"}],"description":[{"notation":[{"@value":"Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence.To present the results from the APCCC 2019.Similar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions.The panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process.Panellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material.These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials.The Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381694366709449731","@type":"Researcher","foaf:name":[{"@value":"Silke Gillessen"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450503","@type":"Researcher","foaf:name":[{"@value":"Gerhardt Attard"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449091","@type":"Researcher","foaf:name":[{"@value":"Tomasz M. Beer"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448197","@type":"Researcher","foaf:name":[{"@value":"Himisha Beltran"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449738","@type":"Researcher","foaf:name":[{"@value":"Anders Bjartell"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449730","@type":"Researcher","foaf:name":[{"@value":"Alberto Bossi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448599","@type":"Researcher","foaf:name":[{"@value":"Alberto Briganti"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448591","@type":"Researcher","foaf:name":[{"@value":"Rob G. Bristow"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448713","@type":"Researcher","foaf:name":[{"@value":"Kim N. Chi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448961","@type":"Researcher","foaf:name":[{"@value":"Noel Clarke"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448970","@type":"Researcher","foaf:name":[{"@value":"Ian D. Davis"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449865","@type":"Researcher","foaf:name":[{"@value":"Johann de Bono"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450251","@type":"Researcher","foaf:name":[{"@value":"Charles G. Drake"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450498","@type":"Researcher","foaf:name":[{"@value":"Ignacio Duran"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448587","@type":"Researcher","foaf:name":[{"@value":"Ros Eeles"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449736","@type":"Researcher","foaf:name":[{"@value":"Eleni Efstathiou"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449475","@type":"Researcher","foaf:name":[{"@value":"Christopher P. Evans"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450373","@type":"Researcher","foaf:name":[{"@value":"Stefano Fanti"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448714","@type":"Researcher","foaf:name":[{"@value":"Felix Y. Feng"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450119","@type":"Researcher","foaf:name":[{"@value":"Karim Fizazi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448451","@type":"Researcher","foaf:name":[{"@value":"Mark Frydenberg"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449986","@type":"Researcher","foaf:name":[{"@value":"Martin Gleave"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450519","@type":"Researcher","foaf:name":[{"@value":"Susan Halabi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450514","@type":"Researcher","foaf:name":[{"@value":"Axel Heidenreich"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448202","@type":"Researcher","foaf:name":[{"@value":"Daniel Heinrich"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448706","@type":"Researcher","foaf:name":[{"@value":"Celestia (Tia) S. Higano"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449870","@type":"Researcher","foaf:name":[{"@value":"Michael S. Hofman"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448960","@type":"Researcher","foaf:name":[{"@value":"Maha Hussain"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449600","@type":"Researcher","foaf:name":[{"@value":"Nicolas James"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448584","@type":"Researcher","foaf:name":[{"@value":"Ravindran Kanesvaran"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448463","@type":"Researcher","foaf:name":[{"@value":"Philip Kantoff"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449095","@type":"Researcher","foaf:name":[{"@value":"Raja B. Khauli"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448967","@type":"Researcher","foaf:name":[{"@value":"Raya Leibowitz"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448833","@type":"Researcher","foaf:name":[{"@value":"Chris Logothetis"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449344","@type":"Researcher","foaf:name":[{"@value":"Fernando Maluf"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449604","@type":"Researcher","foaf:name":[{"@value":"Robin Millman"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450240","@type":"Researcher","foaf:name":[{"@value":"Alicia K. Morgans"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449098","@type":"Researcher","foaf:name":[{"@value":"Michael J. Morris"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448192","@type":"Researcher","foaf:name":[{"@value":"Nicolas Mottet"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448334","@type":"Researcher","foaf:name":[{"@value":"Hind Mrabti"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449868","@type":"Researcher","foaf:name":[{"@value":"Declan G. Murphy"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450371","@type":"Researcher","foaf:name":[{"@value":"Vedang Murthy"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450511","@type":"Researcher","foaf:name":[{"@value":"William K. Oh"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448976","@type":"Researcher","foaf:name":[{"@value":"Piet Ost"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448834","@type":"Researcher","foaf:name":[{"@value":"Joe M. O’Sullivan"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449611","@type":"Researcher","foaf:name":[{"@value":"Anwar R. Padhani"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448332","@type":"Researcher","foaf:name":[{"@value":"Chris Parker"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449482","@type":"Researcher","foaf:name":[{"@value":"Darren M.C. Poon"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448328","@type":"Researcher","foaf:name":[{"@value":"Colin C. Pritchard"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449999","@type":"Researcher","foaf:name":[{"@value":"Robert E. Reiter"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450116","@type":"Researcher","foaf:name":[{"@value":"Mack Roach"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450243","@type":"Researcher","foaf:name":[{"@value":"Mark Rubin"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448836","@type":"Researcher","foaf:name":[{"@value":"Charles J. Ryan"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448468","@type":"Researcher","foaf:name":[{"@value":"Fred Saad"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450374","@type":"Researcher","foaf:name":[{"@value":"Juan Pablo Sade"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450254","@type":"Researcher","foaf:name":[{"@value":"Oliver Sartor"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450377","@type":"Researcher","foaf:name":[{"@value":"Howard I. Scher"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450507","@type":"Researcher","foaf:name":[{"@value":"Neal Shore"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450117","@type":"Researcher","foaf:name":[{"@value":"Eric Small"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450118","@type":"Researcher","foaf:name":[{"@value":"Matthew Smith"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450520","@type":"Researcher","foaf:name":[{"@value":"Howard Soule"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449219","@type":"Researcher","foaf:name":[{"@value":"Cora N. Sternberg"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450370","@type":"Researcher","foaf:name":[{"@value":"Thomas Steuber"}]},{"@id":"https://cir.nii.ac.jp/crid/1420564276175967872","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"60301818"},{"@type":"NRID","@value":"1000060301818"},{"@type":"CINII_AUTHOR_ID","@value":"DA15968086"},{"@type":"URI","@value":"https://ci.nii.ac.jp/author/DA15968086#entity"},{"@type":"URI","@value":"https://viaf.org/viaf/NII%7CDA15968086"},{"@type":"NRID","@value":"9000006685522"}],"foaf:name":[{"@value":"Hiroyoshi Suzuki"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449092","@type":"Researcher","foaf:name":[{"@value":"Christopher Sweeney"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449476","@type":"Researcher","foaf:name":[{"@value":"Matthew R. Sydes"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709449856","@type":"Researcher","foaf:name":[{"@value":"Mary-Ellen Taplin"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448458","@type":"Researcher","foaf:name":[{"@value":"Bertrand Tombal"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448331","@type":"Researcher","foaf:name":[{"@value":"Levent Türkeri"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448594","@type":"Researcher","foaf:name":[{"@value":"Inge van Oort"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709448832","@type":"Researcher","foaf:name":[{"@value":"Almudena Zapatero"}]},{"@id":"https://cir.nii.ac.jp/crid/1381694366709450515","@type":"Researcher","foaf:name":[{"@value":"Aurelius Omlin"}]}],"contributor":[{"@id":"https://cir.nii.ac.jp/crid/1891429165563798915","@type":"Researcher","foaf:name":[{"@value":"DSpace at Acıbadem"}]},{"@id":"https://cir.nii.ac.jp/crid/1891428067458734213","@type":"Researcher","foaf:name":[{"@value":"UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1891428067458733865","@type":"Researcher","foaf:name":[{"@value":"UCL - (SLuc) Service d'urologie"}]},{"@id":"https://cir.nii.ac.jp/crid/1891429165563798913","@type":"Researcher","foaf:name":[{"@value":"De Bono, Johann"}]},{"@id":"https://cir.nii.ac.jp/crid/1891429165563798914","@type":"Researcher","foaf:name":[{"@value":"Eeles, Rosalind"}]},{"@id":"https://cir.nii.ac.jp/crid/1891429165563798912","@type":"Researcher","foaf:name":[{"@value":"James, Nicholas"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03022838"}],"prism:publicationName":[{"@value":"European Urology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2020-04","prism:volume":"77","prism:number":"4","prism:startingPage":"508","prism:endingPage":"547"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://creativecommons.org/licenses/by-nc-nd/4.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0302283820300488?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0302283820300488?httpAccept=text/plain"}],"createdAt":"2020-01-27","modifiedAt":"2025-10-04","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Aging","dc:title":"Aging"},{"@id":"https://cir.nii.ac.jp/all?q=Advanced%20prostate%20cance","dc:title":"Advanced prostate cance"},{"@id":"https://cir.nii.ac.jp/all?q=Hormone-sensitive%20prostate%20cancer","dc:title":"Hormone-sensitive prostate cancer"},{"@id":"https://cir.nii.ac.jp/all?q=Imaging","dc:title":"Imaging"},{"@id":"https://cir.nii.ac.jp/all?q=SALVAGE%20RADIATION-THERAPY","dc:title":"SALVAGE RADIATION-THERAPY"},{"@id":"https://cir.nii.ac.jp/all?q=QUALITY-OF-LIFE","dc:title":"QUALITY-OF-LIFE"},{"@id":"https://cir.nii.ac.jp/all?q=Medicine%20and%20Health%20Sciences","dc:title":"Medicine and Health Sciences"},{"@id":"https://cir.nii.ac.jp/all?q=Overall%20survival","dc:title":"Overall survival"},{"@id":"https://cir.nii.ac.jp/all?q=Neoplasm%20Metastasis","dc:title":"Neoplasm Metastasis"},{"@id":"https://cir.nii.ac.jp/all?q=DISSECTION","dc:title":"DISSECTION"},{"@id":"https://cir.nii.ac.jp/all?q=Cancer","dc:title":"Cancer"},{"@id":"https://cir.nii.ac.jp/all?q=Castration-resistant%20prostate%20cancer","dc:title":"Castration-resistant prostate cancer"},{"@id":"https://cir.nii.ac.jp/all?q=Tumour%20genomic%20profiling","dc:title":"Tumour genomic profiling"},{"@id":"https://cir.nii.ac.jp/all?q=Advanced%20prostate%20cancer","dc:title":"Advanced prostate cancer"},{"@id":"https://cir.nii.ac.jp/all?q=Prostate%20Cancer","dc:title":"Prostate Cancer"},{"@id":"https://cir.nii.ac.jp/all?q=RADICAL%20PROSTATECTOMY","dc:title":"RADICAL PROSTATECTOMY"},{"@id":"https://cir.nii.ac.jp/all?q=Progression-free%20survival","dc:title":"Progression-free survival"},{"@id":"https://cir.nii.ac.jp/all?q=TESTOSTERONE%20MEASUREMENTS","dc:title":"TESTOSTERONE MEASUREMENTS"},{"@id":"https://cir.nii.ac.jp/all?q=ddc:no","dc:title":"ddc:no"},{"@id":"https://cir.nii.ac.jp/all?q=Urology%20%26%20Nephrology","dc:title":"Urology & Nephrology"},{"@id":"https://cir.nii.ac.jp/all?q=High-risk%20localised%20prostate%20cancer","dc:title":"High-risk localised prostate cancer"},{"@id":"https://cir.nii.ac.jp/all?q=Prostate%20cancer%20treatment","dc:title":"Prostate cancer treatment"},{"@id":"https://cir.nii.ac.jp/all?q=Local","dc:title":"Local"},{"@id":"https://cir.nii.ac.jp/all?q=Practice%20Guidelines%20as%20Topic","dc:title":"Practice Guidelines as Topic"},{"@id":"https://cir.nii.ac.jp/all?q=PHASE-II","dc:title":"PHASE-II"},{"@id":"https://cir.nii.ac.jp/all?q=/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being","dc:title":"/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being"},{"@id":"https://cir.nii.ac.jp/all?q=Overall","dc:title":"Overall"},{"@id":"https://cir.nii.ac.jp/all?q=profiling","dc:title":"profiling"},{"@id":"https://cir.nii.ac.jp/all?q=CLINICAL-TRIALS","dc:title":"CLINICAL-TRIALS"},{"@id":"https://cir.nii.ac.jp/all?q=Urologic%20Diseases","dc:title":"Urologic Diseases"},{"@id":"https://cir.nii.ac.jp/all?q=Radboudumc%2015:%20Urological%20cancers%20RIMLS:%20Radboud%20Institute%20for%20Molecular%20Life%20Sciences","dc:title":"Radboudumc 15: Urological cancers RIMLS: Radboud Institute for Molecular Life Sciences"},{"@id":"https://cir.nii.ac.jp/all?q=Urology","dc:title":"Urology"},{"@id":"https://cir.nii.ac.jp/all?q=Clinical%20Sciences","dc:title":"Clinical Sciences"},{"@id":"https://cir.nii.ac.jp/all?q=/dk/atira/pure/subjectarea/asjc/2700/2748","dc:title":"/dk/atira/pure/subjectarea/asjc/2700/2748"},{"@id":"https://cir.nii.ac.jp/all?q=610","dc:title":"610"},{"@id":"https://cir.nii.ac.jp/all?q=Radboud%20University%20Medical%20Center","dc:title":"Radboud University Medical Center"},{"@id":"https://cir.nii.ac.jp/all?q=HOT%20FLASHES","dc:title":"HOT FLASHES"},{"@id":"https://cir.nii.ac.jp/all?q=Bone%20Neoplasms","dc:title":"Bone Neoplasms"},{"@id":"https://cir.nii.ac.jp/all?q=survival","dc:title":"survival"},{"@id":"https://cir.nii.ac.jp/all?q=SDG%203%20-%20Good%20Health%20and%20Well-being","dc:title":"SDG 3 - Good Health and Well-being"},{"@id":"https://cir.nii.ac.jp/all?q=Castration-na%C3%AFve%20prostate%20cancer","dc:title":"Castration-naïve prostate cancer"},{"@id":"https://cir.nii.ac.jp/all?q=Genetics","dc:title":"Genetics"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Castration-nai%CC%88ve%20prostate%20cancer","dc:title":"Castration-naïve prostate cancer"},{"@id":"https://cir.nii.ac.jp/all?q=LYMPH-NODE","dc:title":"LYMPH-NODE"},{"@id":"https://cir.nii.ac.jp/all?q=Neoplasm%20Staging","dc:title":"Neoplasm Staging"},{"@id":"https://cir.nii.ac.jp/all?q=Tumour%20genomic","dc:title":"Tumour genomic"},{"@id":"https://cir.nii.ac.jp/all?q=Prostatic%20Neoplasms","dc:title":"Prostatic Neoplasms"},{"@id":"https://cir.nii.ac.jp/all?q=Prostate-Specific%20Antigen","dc:title":"Prostate-Specific Antigen"},{"@id":"https://cir.nii.ac.jp/all?q=ResearchInstitutes_Networks_Beacons/mcrc;%20name%3DManchester%20Cancer%20Research%20Centre","dc:title":"ResearchInstitutes_Networks_Beacons/mcrc; name=Manchester Cancer Research Centre"},{"@id":"https://cir.nii.ac.jp/all?q=Oligometastatic%20prostate%20cancer","dc:title":"Oligometastatic prostate cancer"},{"@id":"https://cir.nii.ac.jp/all?q=LYMPH-NODE%20DISSECTION","dc:title":"LYMPH-NODE DISSECTION"},{"@id":"https://cir.nii.ac.jp/all?q=Good%20Health%20and%20Well%20Being","dc:title":"Good Health and Well Being"},{"@id":"https://cir.nii.ac.jp/all?q=Neoplasm%20Recurrence","dc:title":"Neoplasm Recurrence"},{"@id":"https://cir.nii.ac.jp/all?q=Urology%20-%20Radboud%20University%20Medical%20Center","dc:title":"Urology - Radboud University Medical Center"},{"@id":"https://cir.nii.ac.jp/all?q=ANDROGEN-DEPRIVATION%20THERAPY","dc:title":"ANDROGEN-DEPRIVATION THERAPY"},{"@id":"https://cir.nii.ac.jp/all?q=Neoplasm%20Recurrence,%20Local","dc:title":"Neoplasm Recurrence, Local"},{"@id":"https://cir.nii.ac.jp/all?q=FREE%20SURVIVAL","dc:title":"FREE SURVIVAL"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040282256893656320","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"16K11030"},{"@type":"JGN","@value":"JP16K11030"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16K11030/"}],"notation":[{"@language":"ja","@value":"去勢抵抗性前立腺癌の新規薬剤耐性の分子機構の解明とオーダーメイド治療への応用"},{"@language":"en","@value":"Elucidation of the molecular mechanism of castration-resistant progression of prostate cancer and its application to precision oncology"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050583933991607680","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002217512648320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004233819471104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142497181824","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144229730560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144508349056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144852664704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Chemotherapy Regimen in Nonagenarian Cancer Patients: A Bi-Institutional Experience"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145382123136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long‐term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145557420032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"NCCN Task Force Report: Bone Health in Cancer Care"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146283128448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations."}]},{"@id":"https://cir.nii.ac.jp/crid/1360282588971425536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283690897416832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617879709440","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618508802176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Oligometastatic prostate cancer: Reality or figment of imagination?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618912883840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618942911360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Predictive Factors of Oncologic Outcomes in Patients Who do not Achieve Undetectable Prostate Specific Antigen after Radical Prostatectomy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619101162496","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effectiveness of Platinum-Based Chemotherapy in Patients With Metastatic Prostate Cancer: Systematic Review and Meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619680964480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620557681152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620828690176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621175350400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"TheraP: a randomized phase 2 trial of\n                    <sup>177</sup>\n                    Lu‐\n                    <scp>PSMA</scp>\n                    ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol\n                    <scp>ANZUP</scp>\n                    1603)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621303147648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302865547064832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092452507776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092520397184","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Whole‐body diffusion‐weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092548158208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092785839488","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574093674135040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094093004416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094335148160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094473250560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical variability and molecular heterogeneity in prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094814416000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094921959936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094964466944","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094995574912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095901505536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096364754432","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118697311744","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinicopathological Analysis of the ISUP Grade Group And Other Parameters in Prostate Cancer: Elucidation of Mutual Impact of the Various Parameters"}]},{"@id":"https://cir.nii.ac.jp/crid/1360579820401250304","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Outcomes of Dose-Attenuated Docetaxel in Asian Patients with Castrate-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567858933504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568822284544","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to curative‐intent surgery or radiotherapy (proPSMA study): clinical trial protocol"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568861684352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569088848896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Intermittent versus Continuous Androgen Deprivation in Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569201594368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569257929216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569350849792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569781295104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lower Testosterone Levels With Luteinizing Hormone-Releasing Hormone Agonist Therapy Than With Surgical Castration: New Insights Attained by Mass Spectrometry"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570217324288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570750325120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855571066888960","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855571258267904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pelvic Lymph Node Dissection in Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855571474449664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593782651008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Metastatic Diffusion Volume Based on Apparent Diffusion Coefficient as a Prognostic Factor in <scp>Castration‐Resistant</scp> Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044111514880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real‐world’ consideration of results from the Advanced Prostate Cancer Consensus Conference\n                    <scp>(APCCC)</scp>\n                    2017"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044370700416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044910537984","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045161004160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of\n                    <i>BRCA2</i>\n                    Reversion Mutations Associated with Resistance to PARP Inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045244870016","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045419332736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045714422400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045777864064","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Docetaxel in very elderly men with metastatic castration-resistant prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045853184640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045894041344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046052800384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046214497664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046484114304","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Clinician’s Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518622052352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518719413120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519085762432","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519208067712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519283761408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519455424384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Intratumor heterogeneity in prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520187853952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520555725568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prevalence and Duration of Hot Flushes After Surgical or Medical Castration in Men with Prostatic Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520699168896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521182735616","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993531016064","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993537653376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994015680896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994159417728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"External Validation of the CAPRA-S Score to Predict Biochemical Recurrence, Metastasis and Mortality after Radical Prostatectomy in a European Cohort"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994244421632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994319125376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994341826560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994441670656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Luteinizing Hormone–Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994865310720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Advances in Urologic Imaging"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994977713280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cancer Control and Complications of Salvage Local Therapy After Failure of Radiotherapy for Prostate Cancer: A Systematic Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995037447808","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995282804352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995436674432","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995457853056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995720176000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995910023680","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995914644352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996021909760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468726289408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468780563328","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468794974976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469058535296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469146932352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hot flashes: behavioral treatments, mechanisms, and relation to sleep"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469197755648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469212397056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC)."}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469250924288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"<scp>NICE</scp>\n                    Guidance – Prostate cancer: diagnosis and management"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469385379072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469487774336","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469533195008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PARP inhibitors for homologous recombination-deficient prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469759166976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469783539584","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469987363840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470392857216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Visceral Disease in Castration-resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470438737280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470478434048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470590561792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis."}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470693173888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470732759296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Standardization of testosterone measurements in humans"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470953963136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981471145290368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943460920192","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of <sup>177</sup>Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)."}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943638220160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Features and Prognostic Significance of Intraductal Carcinoma of the Prostate"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943679033472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943758373376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antiandrogen withdrawal syndrome with cyproterone acetate"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943904743168","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943962042496","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Towards precision oncology in advanced prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944419018496","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945038791808","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945169649792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945432214400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945694913536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945729189120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945798827520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Evolving Role of Prostate-Specific Membrane Antigen–Based Diagnostics and Therapeutics in Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945854353792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946344159104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418621983232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418709158912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418717301632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418780144896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419220668672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function\n                    <i>ERF</i>\n                    Mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419622027520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420600390144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420604256256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Response to olaparib in a <i>PALB2</i> germline mutated prostate cancer and genetic events associated with resistance"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420632189824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199."}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420859767424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420876859392","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544421014336640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544421331257472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Aggressive Variants of Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893265390976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893739268992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894258007808","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)."}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894329223168","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894334675072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894616901120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hot Flushes are Induced by Thermogenic Stimuli"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895394533376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895475887232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178–211"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895609140352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895960697728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895976501632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895979576192","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896040469376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Acupuncture for Hot Flashes in Patients With Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896306406528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896337643008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368315899264","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"New concepts in prostate cancer management: the conundrum of managing oligometastatic disease in prostate cancer—through the looking glass darkly"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368482315648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Oligometastatic prostate cancer: The game is afoot"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368556122240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368557135744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368627689216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)."}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368694895232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370074080000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370151580544","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370226281344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370512025088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370629032832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Utility, Limitations, and Pitfalls in Measuring Testosterone: An Endocrine Society Position Statement"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370895192704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843419846016","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843688215040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844184038400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"CDK12 inactivation across solid tumors: an actionable genetic subtype"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844524272128","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone‐naïve prostate cancer: The first real‐life experience in Asia"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844548589696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term Outcomes of Patients with Lymph Node Metastasis Treated with Radical Prostatectomy Without Adjuvant Androgen-deprivation Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845333606784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845711917696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846035682176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318238466560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318261850880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318703380352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319041698176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319367717632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319506793600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319682939648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320016798848","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from ‘castration-resistant’ prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320223300736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320599444352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Accuracy-based proficiency testing for testosterone measurements with immunoassays and liquid chromatography-mass spectrometry"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320828379904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320839239808","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670321056390784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Duration of Androgen Suppression in the Treatment of Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670321103648768","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670321182678912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793658409728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Toward Excellence in Testosterone Testing: A Consensus Statement"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794412085504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794534006016","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"How to Manage the Obese Patient With Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794572786048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Consensus on molecular imaging and theranostics in prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795236199552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795761796608","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795992425216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951796010709632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951796249141888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268170421248","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268726024320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The influence of BRCA2 mutation on localized prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269074917632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Health Related Quality of Life in Men With Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269361242240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Obesity and Prostate Cancer: Weighing the Evidence"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269426571648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269550239488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Abiraterone and Increased Survival in Metastatic Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269718993152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269820371456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269891591936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269911290752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269952635648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270119263488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270190545536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270396346240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PARP inhibitors in ovarian cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270486372352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270707828224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The association between germline <scp><i>BRCA2</i></scp> variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270759918976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adjuvant radiation with androgen‐deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271131509504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271212775552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1370025024038842112","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Acupuncture for treating hot flushes in men with prostate cancer: a systematic review"}]},{"@id":"https://cir.nii.ac.jp/crid/1370025024038842240","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison"}]},{"@id":"https://cir.nii.ac.jp/crid/1371694366709448195","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Assessment of Real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1371694366709448326","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective comprehensive genomic profiling of primary and metastatic prostate tumors"}]},{"@id":"https://cir.nii.ac.jp/crid/1371694366709448450","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of metastatic prostate cancer in frail/elderly patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1371694366709448967","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prevalence of hypogonadism in low-risk prostate cancer survivors"}]},{"@id":"https://cir.nii.ac.jp/crid/1371694366709449611","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Molecular mechanisms involving prostate cancer racial disparity"}]},{"@id":"https://cir.nii.ac.jp/crid/1371694366709449862","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/1371694366709449984","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bone health in cancer patients: ESMO Clinical Practice Guidelines"}]},{"@id":"https://cir.nii.ac.jp/crid/1371694366709450380","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making"}]},{"@id":"https://cir.nii.ac.jp/crid/1371694366709450504","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.eururo.2020.01.012"},{"@type":"KAKEN","@value":"PRODUCT-23575076"},{"@type":"OPENAIRE","@value":"doi_dedup___::962884013e665ffdebf5e1bab1e81d84"},{"@type":"CROSSREF","@value":"10.1056/nejmoa2022485_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"},{"@type":"CROSSREF","@value":"10.1001/jamanetworkopen.2020.21692_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"},{"@type":"CROSSREF","@value":"10.1080/14737140.2023.2200170_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"},{"@type":"CROSSREF","@value":"10.1056/nejmoa2001342_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"},{"@type":"CROSSREF","@value":"10.1111/iju.14497_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"},{"@type":"CROSSREF","@value":"10.1016/j.urolonc.2020.08.018_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"},{"@type":"CROSSREF","@value":"10.1007/s10147-020-01824-5_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"},{"@type":"CROSSREF","@value":"10.3389/fonc.2021.695251_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"},{"@type":"CROSSREF","@value":"10.1186/s40364-024-00695-6_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"},{"@type":"CROSSREF","@value":"10.1016/j.urolonc.2020.06.033_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"},{"@type":"CROSSREF","@value":"10.1002/jmri.27596_references_DOI_Y1EbwCNie9jPQxqz6STe6kk1nXQ"}]}